TFF Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI
This assessment of TFF Pharmaceuticals Inc was assembled by All Street Sevva using advanced Cognitive Robots. Check the end of this webpage for potential risks for TFF Pharmaceuticals Inc based on industry, location and marketcap. This Sustainability rating for TFF Pharmaceuticals Inc indicates its reporting of the UN SDGs.
TFF Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.2; made up of an environmental score of 2.7, social score of 4.8 and governance score of 8.0.
5.2
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
658 | Transchem Ltd | 5.3 | High |
658 | Zenith Healthcare Ltd | 5.3 | High |
687 | TFF Pharmaceuticals Inc | 5.2 | High |
687 | Cardiol Therapeutics Inc | 5.2 | High |
687 | Cell Source Inc | 5.2 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does TFF Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?
Does TFF Pharmaceuticals Inc disclose current and historical energy intensity?
Does TFF Pharmaceuticals Inc report the average age of the workforce?
Does TFF Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?
Does TFF Pharmaceuticals Inc disclose its ethnicity pay gap?
Does TFF Pharmaceuticals Inc disclose cybersecurity risks?
Does TFF Pharmaceuticals Inc offer flexible work?
Does TFF Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does TFF Pharmaceuticals Inc disclose the number of employees in R&D functions?
Does TFF Pharmaceuticals Inc conduct supply chain audits?
Does TFF Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does TFF Pharmaceuticals Inc conduct 360 degree staff reviews?
Does TFF Pharmaceuticals Inc disclose the individual responsible for D&I?
Does TFF Pharmaceuticals Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does TFF Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?
Does TFF Pharmaceuticals Inc disclose water use targets?
Does TFF Pharmaceuticals Inc have careers partnerships with academic institutions?
Did TFF Pharmaceuticals Inc have a product recall in the last two years?
Does TFF Pharmaceuticals Inc disclose incidents of discrimination?
Does TFF Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?
Has TFF Pharmaceuticals Inc issued a profit warning in the past 24 months?
Does TFF Pharmaceuticals Inc disclose parental leave metrics?
Does TFF Pharmaceuticals Inc disclose climate scenario or pathway analysis?
Does TFF Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does TFF Pharmaceuticals Inc disclose the pay ratio of women to men?
Does TFF Pharmaceuticals Inc support suppliers with sustainability related research and development?
Does TFF Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does TFF Pharmaceuticals Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is TFF Pharmaceuticals Inc involved in embryonic stem cell research?
Does TFF Pharmaceuticals Inc disclose GHG and Air Emissions intensity?
Does TFF Pharmaceuticals Inc disclose its waste policy?
Does TFF Pharmaceuticals Inc report according to TCFD requirements?
Does TFF Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does TFF Pharmaceuticals Inc disclose energy use targets?
Does TFF Pharmaceuticals Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does TFF Pharmaceuticals Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for TFF Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.